Viking Therapeutics (VKTX) Return on Capital Employed (2015 - 2026)
Viking Therapeutics (VKTX) posted Return on Capital Employed of 122.97% for Q2 2026, down 36.11% sequentially from 90.34% in Q1 2026, and down 9687.0% YoY from 1.28% in Q2 2025.
Viking Therapeutics (VKTX) Return on Capital Employed (2015 - 2026) Analysis & Trends
Viking Therapeutics has reported Return on Capital Employed for 12 years, with the latest figure at 122.97% in Q2 2026.
- Quarterly Return on Capital Employed fell 9687.0% year-over-year to 122.97% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 122.97% (down 9687.0% YoY) and the FY2025 annual result came in at 53.49%, down 2879.0% from the prior year.
- Return on Capital Employed fell to 122.97% in Q2 2026 per VKTX's latest filing, from 90.34% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 13.38% in Q2 2024 and troughed at 122.97% in Q2 2026.
- A 5-year average of 39.22% and a median of 30.45% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2026: Return on Capital Employed surged 3381 bps in 2024, then sank 9687 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 48.3% in 2022, then surged by 41 bps to 28.29% in 2023, then jumped by 40 bps to 16.85% in 2024, then slumped by 259 bps to 60.43% in 2025, then sank by 103 bps to 122.97% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 122.97%, 90.34%, and 60.43% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - | -122.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -122.97% |
| Mar 31, 2026 | -90.34% |
| Dec 31, 2025 | -60.43% |
| Sep 30, 2025 | -36.28% |
| Jun 30, 2025 | -26.10% |
| Mar 31, 2025 | -19.85% |
| Dec 31, 2024 | -16.85% |
| Sep 30, 2024 | -14.61% |
| Jun 30, 2024 | -13.38% |
| Mar 31, 2024 | -18.00% |
| Dec 31, 2023 | -28.29% |
| Sep 30, 2023 | -24.27% |
| Jun 30, 2023 | -30.79% |
| Mar 31, 2023 | -51.82% |
| Dec 31, 2022 | -48.30% |
| Sep 30, 2022 | -39.11% |
| Jun 30, 2022 | -34.48% |
| Mar 31, 2022 | -30.12% |
| Dec 31, 2021 | -26.67% |
| Sep 30, 2021 | -24.77% |